Single agent umbralisib effective for relapsed slow-growing lymphoma
A study at The University of Texas MD Anderson Cancer Center revealed the investigational drug umbralisib as an effective treatment for patients with relapsed marginal zone lymphoma (MZL). Findings from the Phase II trial were presented by study co-lead Nathan Fowler, M.D., associate professor in the Department of Lymphoma & Myeloma, at the AACR Annual Meeting 2019 in Atlanta.
MZL is a low-grade non-Hodgkin lymphoma that accounts...
New potential therapeutic target for pancreatic cancer discovered
Cancer cells demand enormous amounts of molecular “food” to survive and grow, and a study published March 27 online in Nature by researchers...
Study may explain why immunotherapy not effective for some patients with metastatic melanoma and kidney cancer
White blood cells known as B cells have been shown to be effective for predicting which cancer patients will respond to immune checkpoint...
Study points to new strategy for boosting immunotherapy effectiveness in advanced colorectal cancer
Researchers at The University of Texas MD Anderson Cancer Center revealed the common oncogene KRAS as a possible explanation for why many patients with metastatic colorectal cancer (CRC) do not respond to immune checkpoint blockade (ICB) therapy.
Findings from the study, published in the March 21 online issue of Cancer Cell, shows how KRAS, a key mutation in colorectal cancer, promotes metastasis by controlling the immune-suppressive...
MD Anderson's Making Cancer History Seminar heads to New Orleans
The University of Texas MD Anderson Cancer Center presents its Making Cancer History® Seminar, 11:30 a.m.-1:30 p.m. March 25 at the Hotel...
New report finds states must do more to ensure people at high risk can be screened for lung cancer
Lung cancer is the leading cancer killer, yet coverage of screenings for individuals at high risk for lung cancer varies across state Medicaid...
ZEB1 throttles therapeutic target, protecting KRAS-mutant lung cancer
A cellular identity switch protects a cancer-promoting genetic pathway from targeted therapy, researchers at The University of Texas MD Anderson...
MD Anderson to present Making Cancer History Seminar in Palm Beach
The University of Texas MD Anderson Cancer Center returns to Palm Beach with its Making Cancer History® Seminar, 9-11 a.m. March 18 at The...
Giulio Draetta named Chief Scientific Officer
The University of Texas MD Anderson Cancer Center has named Giulio Draetta, M.D., Ph. D. as chief scientific officer (CSO), a new position...